Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

922.842
-7.905-0.85%
Number of Gainers:4
Number of Losers:8
Number of Flat:1
PE:- -
High:933.426
Open:931.184
Low:920.261
Close:930.747
Volume:70.05M
Turnover:515.89M
Market Cap:151.95B
Float Cap:113.75B

Loading ...

Sinopharm Group Stock Rallies 1.1% in Hong Kong

Dow Jones
·
Aug 26

Global Equities Roundup: Market Talk

Dow Jones
·
Aug 26

Fosun Pharma's H1 Report: Innovative Drug Revenue Surges 13.8% as Global Expansion Spans Three Continents

Deep News
·
Aug 26

SIHUAN PHARM Posts 119% Profit Surge in Interim Results, Reinforcing Dual-Engine Strategy

Stock News
·
Aug 26

Sihuan Pharmaceutical H1 Profit Jumps on Medical Aesthetics Unit Strength

Reuters
·
Aug 26

Sihuan Pharmaceutical Holdings Group H1 Net Income Attributable RMB 224.7 Million

THOMSON REUTERS
·
Aug 26

Sihuan Pharma Appoints Song Xiaomi as CFO

Reuters
·
Aug 26

Sihuan Pharma - Appoints Song Xiaomi as Chief Financial Officer Effective 26 August 2026

THOMSON REUTERS
·
Aug 26

Sihuan Pharma - Miao Guili Resigns as Executive Director, Deputy CEO, and CFO Effective 26 August 2026

THOMSON REUTERS
·
Aug 26

Fosun Pharma Posts Flat Profit Growth in H1, Revenue Up 4.8%

MT Newswires Live
·
Aug 26

Press Release: Fosun Pharma Announces 2026 Interim Results

Dow Jones
·
Aug 25

Haohai Biotec Allocates HK$3.94 Million to Buy Back Nearly 250,000 Shares

Stock News
·
Aug 24

Sinopharm Group Stock Falls 1.9% in Hong Kong

Dow Jones
·
Aug 24

CICC Keeps Outperform Rating on 3SBIO, Trims Target Price to HK$30.00

Stock News
·
Aug 24

Shanghai Haohai Biological Technology (SEHK:6826) Stock Hit By Margin Compression And Profit Drop

Simply Wall St.
·
Aug 23

HAOHAI BIOTEC Sets October Dividend Date for Interim Payout

Stock News
·
Aug 21

China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution

Reuters
·
Aug 21

3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline

Simply Wall St.
·
Aug 21

3SBio H1 FY26 Net Profit Rises 26.5% to RMB 1.44 Billion; Revenue Increases 3.9% to RMB 4.53 Billion

Reuters
·
Aug 21

Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

Dow Jones
·
Aug 21